High Dose IL-2

DRUG5 trials

Sponsors

H. Lee Moffitt Cancer Center and Research Institute, Providence Health & Services, Iovance Biotherapeutics, Inc., Vall d'Hebron Institute of Oncology

Conditions

Cervical CancerChronic Lymphocytic LeukemiaMelanomaMetastatic MelanomaNon Small Cell Lung CancerRenal Cell CarcinomaSmall Lymphocytic Lymphoma

Phase 1

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

CompletedNCT04155710

Iovance Biotherapeutics, Inc.Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Start: 2020-02-19End: 2024-12-02Updated: 2025-12-24

Phase 2

Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

Active, not recruitingNCT02306954

Providence Health & ServicesRenal Cell Carcinoma

Start: 2014-12-31End: 2026-12-31Target: 84Updated: 2025-03-10

Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)

RecruitingNCT06630611

Vall d'Hebron Institute of OncologyCervical Cancer, Melanoma, Non Small Cell Lung Cancer

Start: 2025-01-15End: 2029-09-30Target: 40Updated: 2025-01-28

Unknown Phase

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

CompletedNCT01005745

H. Lee Moffitt Cancer Center and Research InstituteMetastatic Melanoma

Start: 2009-10-20End: 2025-08-18Updated: 2025-12-19

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

CompletedNCT01701674

H. Lee Moffitt Cancer Center and Research InstituteMetastatic Melanoma

Start: 2012-10-09End: 2025-08-21Updated: 2025-12-19

Related Papers

Impact of clonal hematopoiesis on hematologic recovery and outcomes following tumor-infiltrating lymphocyte therapy

Blood2025-11-03

CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion

Journal for ImmunoTherapy of Cancer2025-04-016 citations

Recent Advancements in Cell-Based Therapies in Melanoma.

2024-09-124 citations

Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of Iov-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Blood2021-11-05

384 An investigation into the role of CD4+ tumor-infiltrating lymphocytes (TIL) in metastatic melanoma patients with a complete response to adoptive cell therapy

Regular and Young Investigator Award Abstracts2021-11-01

385 Identification and enrichment of neoantigen-reactive T cells to optimize adoptive cell transfer with tumor-infiltrating lymphocytes (TIL)

Regular and Young Investigator Award Abstracts2021-11-01

Abstract CT244: A Phase 1/2 study evaluating the safety and efficacy of IOV-2001 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

Cancer Research2021-07-01

Final report of a pilot trial combining ipilimumab and adoptive cell therapy.

Journal of Clinical Oncology2017-03-012 citations